SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

Last updated: N/A
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cardiovascular Disease

Treatment

N/A

Clinical Study ID

TX216577
  • Ages 45-100
  • All Genders

Study Summary

This study will look mainly at the effect of semaglutide on cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease.

Approximately 17,500 men and women across the world will take part in this study.

Eligibility Criteria

Inclusion

  • You have previously had a heart attack (myocardial infarction) or brain attack (stroke) or have been diagnosed with poor circulation (peripheral arterial disease).
  • You are 45 years of age or above.
  • You are living with overweight or obesity.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

  • The drug Semaglutide works like your body’s own hormone to regulate your blood sugar (glucose) level and your appetite.
  • If you receive semaglutide and it is effective for you, your risk of having a cardiovascular event may be reduced.
  • You will receive a compensation for each study visit.
  • The sponsor will pay for the cost of the study medicine, tests and checks.
  • Researchers have tested semaglutide in more than 5000 people.